News
Reducing Maternal Mortality in the United States through Collaboration
New training program by Birth Control Pharmacist and Provide includes pharmacy best practices to combat stigma and communication guides and online resources to help connect patients with local resources.
New Webinar Prepares Pharmacists to Provide Reproductive Health Services and Referrals
New training program by Birth Control Pharmacist and Provide includes pharmacy best practices to combat stigma and communication guides and online resources to help connect patients with local resources.
Meet Phexxi – A New Non-Hormonal Contraceptive Gel
About the Product Lactic acid, citric acid, and potassium bitartrate (Phexxi, Evofem Biosciences) is a prescription combination, non-hormonal contraceptive gel approved by the FDA in May 2020. The vaginal gel was found to be 86.3% effective with typical use when inserted up to 1 hour before vaginal intercourse.1 The gel acts as a contraceptive by…
Clinical Considerations for Contraception During COVID: Extended Duration of IUDs and Implants
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.
5 Pearls from the 2020 States Forum on Pharmacist Birth Control Services
The second annual States Forum on Pharmacist Birth Control Services recently was held by the Birth Control Pharmacist project in partnership with the National Alliance of State Pharmacy Associations (NASPA). Due to the coronavirus disease 2019 (COVID-19) pandemic, this year’s meeting was held virtually as representatives from across the United States, as well as Canada,…
Contraception During COVID: California’s Medi-Cal and FamilyPACT Programs Cover Depo-SubQ Provera
We recently wrote about the importance of offering patients subcutaneous depot medroxyprogesterone acetate (DMPA-SQ) as a contactless form of contraception during the COVID-19 public health emergency. California pharmacists can prescribe DMPA-SQ under statewide protocol upon completing the required training program and obtain payment for the visit for Medi-Cal patients. As of April 9, 2020, California’s…
Clinical Considerations for Contraception During COVID: Patient Self-Administration
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.
- « Previous
- 1
- 2
- 3
- Next »